Literature DB >> 9024256

Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins.

A W Meikle1, R A Stephenson, C M Lewis, R G Middleton.   

Abstract

Benign prostatic hyperplasia has been shown to increase with age and be influenced by sex hormones. The relationship between aging and hormonal influences on growth of zones of the prostate is unresolved. We studied the relationship of age and sex hormones on volume of prostate zones in 214 male twins between 25 and 75 yr old. Volumes of the total prostate (TV), transition zone (TZ), and peripheral zones (PZ) were measured using transrectal ultrasound, and sex steroid concentrations were measured using RIA. Using transformed data corrected for age, TV (r = 0.54, P < 0.00001), TZ (r = 0.58, P < 0.00001), and PZ (r = 0.39, P < 0.00001) volumes increased with age. However, the PZ volume rose more rapidly than the TZ before age 50, and TZ showed a steeper increase after age 50 yr than the PZ volume. The TZ, PZ, and ratio TZ/PZ correlated significantly (r = 0.87, 0.90, and 0.52, respectively; P < 0.00001). After a TV exceeded 30 g, the rise of the PZ became attenuated, and the slope of the TZ became steeper. Age-adjusted sex hormone concentration was not evaluated in men with larger prostate volumes. Men with American Urological Association symptom scores above 10 had significantly (P < 0.001) larger total prostate volume (TV) and TZ volume, but not PZ volumes, than men with scores below 10. Prostate volumes correlated inversely with age-adjusted serum testosterone (T), dihydrotestosterone, sex hormone binding globulin, and sex hormone binding globulin-bound T concentrations. These results demonstrate that before age 50 yr or before a prostate weight exceeds 30 g, prostate growth may be mainly from enlargement of the PZ and after age 50, the TZ. In addition, elevated T and dihydrotestosterone concentrations do not predispose men to prostate enlargement or symptoms of benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024256     DOI: 10.1210/jcem.82.2.3720

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Andropause: is the emperor wearing any clothes?

Authors:  S H Tariq; M T Haren; M J Kim; J E Morley
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

Review 2.  Prostate zones and cancer: lost in transition?

Authors:  Amin Ali; Alexander Du Feu; Pedro Oliveira; Ananya Choudhury; Robert G Bristow; Esther Baena
Journal:  Nat Rev Urol       Date:  2021-10-19       Impact factor: 14.432

Review 3.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Testosterone replacement therapy and prostate health.

Authors:  A Scott Polackwich; Kevin A Ostrowski; Jason C Hedges
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

5.  Effects of Testosterone on Benign and Malignant Conditions of the Prostate.

Authors:  Amin S Herati; Taylor P Kohn; Peter R Butler; Larry I Lipshultz
Journal:  Curr Sex Health Rep       Date:  2017-04-26

6.  Impact of perioperative factors on nadir serum prostate-specific antigen levels after holmium laser enucleation of prostate.

Authors:  Mary Martos; Jonathan E Katz; Madhumita Parmar; Anika Jain; Nachiketh Soodana-Prakash; Sanoj Punnen; Mark L Gonzalgo; Feng Miao; Isildinha M Reis; Nicholas Smith; Hemendra N Shah
Journal:  BJUI Compass       Date:  2021-01-05

Review 7.  Schema and cancer detection rates for transperineal prostate biopsy templates: a review.

Authors:  Abhinav Sidana; Fernando Blank; Hannah Wang; Nilesh Patil; Arvin K George; Hasan Abbas
Journal:  Ther Adv Urol       Date:  2022-06-26

8.  Relationship between serum total testosterone and prostate volume in aging men.

Authors:  Bo-Wen Xia; Si-Cong Zhao; Zong-Ping Chen; Chao Chen; Tian-Shu Liu; Fan Yang; Yong Yan
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.